Investigational drug · Phase 2
preferred combination of tinengotinib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostate Cancer (CRPC).
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "preferred combination of tinengotinib"
First trial start
2026
Sep 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "preferred combination of tinengotinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer (CRPC)
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "preferred combination of tinengotinib" as an intervention, largest first.
- Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
TransThera Sciences (Nanjing), Inc.Industry
NCT07871110 · 182 participants (planned) · Start Sep 18, 2026 · Primary completion Dec 31, 2028
Drug: tinengotinib 10 mg QD plus darolutamide; tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide and 5 more · For: Prostate Cancer (CRPC)
Sites: Fuzhou, China; Guangzhou, China; Wuhan, China · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostate Cancer (CRPC)
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- selected combination of tinengotinibPhase 21 trial
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.